An insulinotropic polypeptide signals the pancreas to release insulin. Learn how GIP works, how it differs from GLP-1, and whether supplements exist.
An insulinotropic polypeptide is a hormone that tells the pancreas to release insulin. The best-known example is glucose-dependent insulinotropic polypeptide (GIP), a 42-amino acid hormone released by the small intestine after a meal. GIP is one of the two major incretin hormones, and it only amplifies insulin release when blood glucose is already elevated.
What "Insulinotropic" Means
"Insulinotropic" describes anything that prompts pancreatic beta cells to secrete insulin. The term combines insulin with the Greek root "tropos," meaning to turn or direct. An insulinotropic polypeptide is therefore a signaling molecule, not a nutrient and not a drug.
If you are asking what is a polypeptide, it is simply a short chain of amino acids linked by peptide bonds. The polypeptide structure of GIP is a single, unbranched chain of 42 amino acids. Familiar polypeptide examples include insulin, glucagon, GLP-1, and GIP itself.
GIP: The Main Insulinotropic Polypeptide
GIP was first called gastric inhibitory polypeptide because early research focused on its ability to slow stomach acid production. Scientists later found that its effect on insulin mattered far more, so the name glucose-dependent insulinotropic polypeptide became standard. Both names describe the same hormone.
GIP is produced by K cells lining the upper small intestine. Blood levels rise within minutes of eating, often before much glucose reaches the bloodstream. That timing helps explain why the incretin effect is so fast and why it accounts for such a large share of post-meal insulin.
How GIP Triggers Insulin Release
GIP binds to GIP receptors on pancreatic beta cells. The receptor signals through cyclic AMP, which amplifies the insulin secretion that glucose already triggered. Because the effect depends on glucose, GIP does relatively little when blood sugar is normal or low.
The polypeptide group known as incretins — GIP and GLP-1 — is responsible for roughly 50% to 70% of post-meal insulin release in healthy adults. GLP-1 adds separate actions: it slows stomach emptying, reduces glucagon, and increases feelings of fullness.
Native GIP is broken down quickly by the enzyme DPP-4, giving it a half-life of only a few minutes. That short window is one reason researchers rely on modified peptides and receptor agonists rather than the natural hormone.
| Feature | GIP | GLP-1 |
|---|---|---|
| Produced by | K cells in the upper small intestine | L cells in the lower small intestine and colon |
| Amino acid length | 42 | 30 (active forms) |
| Effect on insulin | Amplifies glucose-stimulated release | Amplifies glucose-stimulated release |
| Other actions | May influence glucagon, bone, and fat storage | Slows gastric emptying, lowers glucagon, increases satiety |
| Drugs that target it | Tirzepatide (dual GIP/GLP-1 agonist) | Semaglutide, liraglutide, dulaglutide |
Insulinotropic Polypeptides in Medicine
Tirzepatide is the clearest clinical success tied to GIP biology. It activates both the GIP and GLP-1 receptors and is FDA-approved as Mounjaro for type 2 diabetes and as Zepbound for chronic weight management. Stand-alone GIP analogs have not performed well as weight-loss drugs on their own.
Early GIP-based obesity research stalled because those compounds did not also engage GLP-1 pathways. Researchers continue to study GIP in bone metabolism, fatty tissue, and inflammation. None of those lines of work has produced an approved therapy outside the dual-agonist class.
Are There Insulinotropic Polypeptide Supplements?
No glucose-dependent insulinotropic polypeptide supplement is FDA-approved for human use in the United States. GIP is a peptide hormone, and oral peptides are typically digested into amino acids before they can reach the bloodstream in active form. A capsule is therefore unlikely to deliver meaningful amounts of a working hormone.
The FDA does not review dietary supplements for effectiveness before they are sold, so labels implying insulin-like benefits deserve skepticism. Anyone taking diabetes medication should talk with a healthcare professional before adding a blood sugar product of any kind.
Safety Considerations
- Incretin-based prescription drugs commonly cause nausea, vomiting, and diarrhea, especially during the first weeks.
- Combining glucose-lowering medication with insulin or sulfonylureas raises the risk of hypoglycemia.
- Rare cases of pancreatitis and gallbladder disease have been reported with GLP-1-based therapies.
- People with a history of pancreatitis, kidney disease, or medullary thyroid cancer in the family should discuss risks with a clinician.
Persistent vomiting, severe abdominal pain, or symptoms of low blood sugar warrant prompt medical attention. GIP by itself is unlikely to cause hypoglycemia because its insulin-boosting effect is glucose-dependent.
Key Takeaways
- An insulinotropic polypeptide stimulates insulin release, and GIP is the primary example in humans.
- GIP's effect on insulin is glucose-dependent, so it does not normally drive blood sugar dangerously low on its own.
- No insulinotropic polypeptide supplement is FDA-approved for human use in the United States.
- Tirzepatide is the only FDA-approved drug that targets the GIP receptor, and it also activates GLP-1.
Frequently Asked Questions
What does glucose-dependent insulinotropic polypeptide do?
GIP is a hormone released by K cells in the small intestine after you eat. It travels to the pancreas and amplifies insulin release, but only when blood glucose is already elevated. It also appears to play secondary roles in fat storage and bone metabolism.
Is GIP the same thing as GLP-1?
No. GIP and GLP-1 are two different incretin hormones. GIP is a 42-amino acid peptide made in the upper small intestine, while GLP-1 is a 30-amino acid peptide made in the lower intestine and colon. GLP-1 slows stomach emptying and reduces glucagon, actions that GIP largely lacks.
Are there GIP supplements that actually work?
There is no FDA-approved glucose-dependent insulinotropic polypeptide supplement in the United States. Oral peptides are usually broken down during digestion, so a pill is unlikely to deliver active GIP. The FDA does not evaluate supplement effectiveness before sale, so marketing claims should be treated with caution.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.